BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data

Objective: Mouse Patient-Derived Xenograft (PDX) models are essential tools for evaluating experimental therapeutics. Baylor College of Medicine (BCM) established a PDX Core to provide technical support and infrastructure for PDX-based research. To manage PDX collections effectively, de-identified patient clinical and omics data, as well as PDX-related information and omics data, must be curated and stored. Data must then be analyzed and visualized for each case. To enhance PDX collection management and data dissemination, the BCM Biomedical Informatics Core created the BCM PDX Portal (https://pdxportal.research.bcm.edu/). Materials and Methods: Patient clinical data are abstracted from medical records for each PDX and stored in a central database. Annotations are reviewed by a clinician and de-identified. PDX development method and biomarker expression are annotated. DNAseq, RNAseq, and proteomics data are processed through standardized pipelines and stored. PDX gene expression (mRNA/protein), copy number alterations, and mutations can be searched in combination with clinical markers to identify models potentially useful as a PDX cohort. Results: PDX collection management and PDX selection of models for drug evaluation are facilitated using the PDX Portal. Discussion: To improve the translational effectiveness of PDX models, it is beneficial to use a tool that captures and displays multiple features of the patient clinical and molecular data. Selection of models for studies should be representative of the patient cohort from which they originated. Conclusion: The BCM PDX Portal is a highly effective PDX collection management tool allowing data access in a visual, intuitive manner thereby enhancing the utility of PDX collections. ### Competing Interest Statement FINANCIAL CONFLICTS OF INTEREST: MTL is Founder of, and an uncompensated Limited Partner in, StemMed Ltd. and a Founder of, and uncompensated Manager in StemMed Holdings, its General Partner. MTL is also a Founder of, and Equity Holder in, Tvardi Therapeutics Inc. L.E.D. is a compensated employee of StemMed Ltd. Some PDXs are exclusively licensed to StemMed Ltd. resulting in royalty income to L.E.D.